COVID-19 Email Listserv: Talk to Other Health Care Professionals Have a question about COVID-19 that isn’t answered on this page? Sign up for the COVID-19 listserv. This is a free resource meant for all health care professionals to help you prevent, treat and reduce the impact of the coronavirus crisis. Vaccine Manufacturer Updates

Medical expenditures for cancer care are estimated to top $158 billion (in 2010 dollars) in 2020, representing nearly a 30% increase compared with 2010.1 Adequate access to cancer care continues to be a challenge due to the closing of community-based cancer practices in the United States. The 2018 Community Oncology Alliance (COA) Practice Impact Report

PTAC Application Demonstrates Community Oncology’s Continued Leadership in Providing Solutions to Cancer Care Cost and Quality Challenges The Community Oncology Alliance (COA) has submitted an innovative and ambitious reform model to improve quality, reduce costs, and provide important additional cancer care services to patients, caregivers, and survivors. Known as the “OCM 2.0”, the detailed

Oncology treatment advances continue to evolve at a rapid pace, with immuno-oncology (I-O) therapy at the forefront given its efficacy and tolerability across different tumor types. The last few years have seen fast-track approvals, promising clinical responses, and significant investment from both pharmaceutical companies and venture capital firms. Various forms of I-O therapy exist,

Florida Cancer Specialists and Research Institute, Gainesville; Xcenda, Palm Harbor, FL; and IntrinsiQ, Fresno, AZ Corresponding author: Lucio Gordan, MD, Florida Cancer Specialists and Research Institute, Division of Quality and Informatics, 6420 W Newberry Rd, Suite 100, Gainesville, FL 32605; e-mail: lgordan@flcancer.com. Disclosures provided by the authors are available with this article at jop.ascopubs.org.

Recently, the Medicare Payment Advisory Commission (MedPAC) and other stakeholders have proposed changes to the Medicare Part B drug reimbursement policy. Two suggested approaches include: Revamping the previously tested Part B Competitive Acquisition Program, now dubbed by MedPAC, as the “Drug Value Program” (DVP). The DVP is described as a pharmacy benefit manager (PBM)